{{위키데이터 속성 추적}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 470474559
| IUPAC_name = ''N''-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
| image = Sulpiride.svg
| width = 240px
| image2 = Sulpiride ball-and-stick.png
| width2 = 220px

<!--Clinical data-->
| tradename = Dogmatil, others
| Drugs.com = {{drugs.com|international|sulpiride}}
| pregnancy_category = 
| legal_UK = POM
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]] ([[tablet (pharmacy)|tablets]], [[capsule (pharmacy)|capsules]], [[solution]]), [[intramuscular injection]]

<!--Pharmacokinetic data-->
| bioavailability = 25–40%<ref name=EMC>{{웹 인용| title = Sulpiride Tablets 200mg, 400mg (SPC) | work = electronic Medicines Compendium (eMC) | publisher = Sanofi | date = 21 January 2010 | accessdate = 19 October 2013 | url = http://www.medicines.org.uk/emc/medicine/18936/SPC/Sulpiride+Tablets+200mg%2c+400mg/#PHARMACODYNAMIC_PROPS | url-status = dead | archiveurl = https://web.archive.org/web/20131019145134/http://www.medicines.org.uk/emc/medicine/18936/SPC/Sulpiride+Tablets+200mg%2c+400mg/#PHARMACODYNAMIC_PROPS | archivedate = 19 October 2013 | df =  }}</ref><ref name = Pharm>{{저널 인용| title = Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans|author1=Bressolle, F |author2=Brès, J |author3=Fauré-Jeantis, A | journal=Journal of Pharmaceutical Sciences | pmid = 1619566 | volume = 81 | issue = 1 | pages = 26–32 | date = January 1992 | doi=10.1002/jps.2600810106}}</ref>
| protein_bound = <40%<ref name = EMC/>
| metabolism = Not [[metabolism|metabolized]]<ref>{{저널 인용|title = Metabolism of sulpiride in man and Rhesus monkey|author1=Imondi, AR |author2=Alam, AS |author3=Brennan, JJ |author4=Hagerman, LM | journal = Archives Internationales de Pharmacodynamie et de Thérapie | volume = 232 | issue = 1 | pages = 79–91 | pmid = 96745 | date = March 1979}}</ref>
| elimination_half-life = 6–8 hours<ref name = EMC/>
| excretion = [[Urine]] (70–90%)<ref name = Pharm/><br />[[Feces]] (~95% as the unchanged drug)<ref name = EMC />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 15676-16-1
| ATC_prefix = N05
| ATC_suffix = AL01
| PubChem = 5355
| IUPHAR_ligand = 5501
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00391
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5162
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7MNE9M8287
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01226
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 26
| synonyms = 

<!--Chemical data-->
| C=15 | H=23 | N=3 | O=4 | S=1
| molecular_weight = 341.427 g/mol
| SMILES = O=S(=O)(N)c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BGRJTUBHPOOWDU-UHFFFAOYSA-N
}}
'''설피리드'''(Sulpiride)는 [[벤즈아마이드]](benzamide) 계열의 속하는 항정신성 약의 하나이다. 주로 [[조현증]]과 [[주요우울장애]](major depressive disorder)를 치료하기 위해서 사용된다. 설피리드는 유럽과 일본 등 동아시아 국가에서 주로 사용되므로, 국내 업체인 [[명인제약]]의 경우, '설피딘'이라는 처방 의약품으로 1998년에 허가되었다. Levosulpiride는 Sulpiride의 leve-이성질체를 정제하여 인도에서 같은 용도로 판매하고 있다. 미국이나 캐나다에서는 아직 사용이 허가되지 않았다. 이 약은 강력한 화학물이고 항정신성 amisulpride와 치료적으로 비슷하게 연관되어 있다.

== 각주 ==
{{각주}}

{{항정신병제제}}

[[분류:페놀 에터]]
[[분류:피롤리딘]]
[[분류:벤즈아마이드]]
[[분류:젖분비촉진제]]